Oncotarget

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2017; 8(2):3761.

Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer

Martina Kluth, Ramin Ahrary, Claudia Hube-Magg, Malik Ahmed, Heinke Volta, Catina Schwemin, Stefan Steurer, Corinna Wittmer, Waldemar Wilczak, Eike Burandt, Till Krech, Meike Adam, Uwe Michl, Hans Heinzer, Georg Salomon, Markus Graefen, Christina Koop, Sarah Minner, Ronald Simon _, Guido Sauter and Thorsten Schlomm

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:27966-27979. https://doi.org/10.18632/oncotarget.4626

Metrics: PDF 637 views  |   HTML 1249 views  |   ?  


Abstract

Martina Kluth1, Ramin Ahrary1, Claudia Hube-Magg1, Malik Ahmed1, Heinke Volta1, Catina Schwemin1, Stefan Steurer1, Corinna Wittmer1, Waldemar Wilczak1, Eike Burandt1, Till Krech1, Meike Adam2, Uwe Michl2, Hans Heinzer2, Georg Salomon2, Markus Graefen2, Christina Koop1, Sarah Minner1, Ronald Simon1, Guido Sauter1, Thorsten Schlomm2,3

1Institute of Pathology, University Medical Center Hamburg-Eppendorf, Germany

2Martini-Klinik, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Germany

3Dept. of Urology, Section for translational prostate cancer research, University Medical Center Hamburg-Eppendorf, Germany

Correspondence to:

Ronald Simon, e-mail: r.simon@uke.de

Keywords: 12p deletion, prostate cancer, CDKN1B, p27, prognostic marker

Received: May 27, 2015     Accepted: July 03, 2015     Published: July 21, 2015

ABSTRACT

Deletion of 12p is a recurrent alteration in prostate cancer, but the prevalence and clinical consequences of this alteration have not been studied in detail. Dual labeling fluorescence in situ hybridization using probes for 12p13 (CDKN1B; p27) and centromere 12 as a reference was used to successfully analyze more than 3700 prostate cancers with clinical follow-up data assembled in a tissue microarray format. CDKN1B was selected as a probe because it is located in the center of the deletion, which spans > 10 Mb and includes > 50 genes in 80% of cancers with 12p deletion. Deletion of 12p was found in 13.7% of cancers and included 13.5% heterozygous and 0.2% homozygous deletions. 12p deletion were linked to advanced tumor stage (p < 0.0001), high Gleason grade (p < 0.0001), rapid tumor cell proliferation (p < 0.0001), lymph node metastasis (p = 0.0004), and biochemical recurrence (p = 0.0027). Multivariate analysis including pT stage (p < 0.0001), Gleason grade (p < 0.0001), pN status (p = 0.0001), preoperative PSA levels (p = 0.0001), and resection margin status (p = 0.0001) revealed an independent prognostic value of 12p deletion (p = 0.0014). Deletion of 12p was unrelated to the ERG fusion status. Deletion of 12p was only marginally linked to reduced p27 expression, which by itself was unrelated to clinical outcome. This argues against p27 as the key target gene of 12p deletions. In summary, the results of our study demonstrate that 12p deletion is frequent in prostate cancer and provides independent prognostic information. 12p deletion analysis alone, or in combination with other prognostic parameters may thus have clinical utility.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4626